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The goal of this study was to determine what region of the Dkk-1 promoter was
required for expression of the Dkk-1 gene under different growth conditions. Dkk-1
promoter activity was analyzed in NIH3T3 cell lines stably transfected with luciferase
vectors containing 1068, 535, and 228 bp of Dkk-1 upstream sequence that were
growing, confluent, serum starved and during the cell cycle. Dkk-1 promoter activity
was also analyzed in the cell lines treated with the inhibitors aphidicolin, methotrexate,
and U0126. In general, we found that Dkk-1 promoter activity is higher in a growing cell
population than in a nondividing population. The 1068 Dkk-1 promoter construct does
not appear to change dramatically during the cell cycle nor is it sensitive to an S phase
inhibitor or U0126. Methotrexate treatment was found to decrease promoter activity. A
sequence region between 1068 and 535 appears to be important for regulation of Dkk-1
promoter activity.
2
REGULATION OF THE DICKKOPF-1 PROMOTER SEQUENCES UNDER
VARIOUS GROWTH CONDITIONS
By
Jasmin Denee’ Feimster
A Thesis submitted to
The Faculty of the Graduate School at
The University of North Carolina at Greensboro
In Partial Fulfillment
of the Requirements for the Degree
Master of Science
Greensboro
2006
Approved by
___________________________
Committee Chair
3
To the Feimster, Cherry, Brown, Hyman, and Houpe families;
My gratitude for your support is immeasurable.
ii
4
APPROVAL PAGE
This thesis has been approved by the following committee of the Faculty of the Graduate
School at The University of North Carolina at Greensboro
Committee Chair__________________________________________
Karen Katula
Committee Members __________________________________________
Amy Adamson
__________________________________________
Paul Steimle
___________________________
Date of acceptance by Committee
___________________________
Date of Final Oral Examination
iii
5
ACKNOWLWDGEMENTS
The success of this project is largely due to the tireless effort and dedication of Dr. Karen
Katula. I have learned a great deal while under your tutelage. You are truly a mad
scientist! I would also like to thank my Committee Members Dr. Amy Adamson and Dr.
Paul Steimle. You are both great scientists and educators. I want to acknowledge the
Biology Department of the University of North Carolina at Greensboro for support and
guidance and NIEHS for funding. Finally I would like to wish my laboratory
counterparts Bupathi Dissaynsike, Brian Cooley, Kelli Walters, and LeslieAnn Guerra;
good luck and all the best.
iv
6
TABLE OF CONTENTS
Page
LIST OF TABLES……………………………………………………………………….vii
LIST OF FIGURES……………………………………………………………..………viii
CHAPTER
I. INTRODUCTION………………………………………………………….1
Background……………………………………………………………. 2
Regulation of Cell Growth and Division…………………….…....2
The Wnt Signaling pathway and Control of Cell Growth and
Differentiation ………………………………………………..…4
Dkk-1 Structure and Function……………………………………..5
Role of Dkk-1 in Cell Proliferation………………...……….…….7
Regulation of Dkk-1 gene expression……………..…………...….8
Project Goals and Overview……………………………………………11
II. MATERIALS AND METHODS…………………………………………..13
Cell culture……………………………………………………………..13
Preparation of Stable Cell lines………………………………………...13
Collection of Cells for Promoter Analysis Studies….………………....14
Growing and Confluent Cell Populations……………………………...15
Serum Starved and a Growing Cell Population………………………..15
Cell cycle Analysis…………………………………………………….16
Treatment with Inhibitors……………………………………………...16
Aphidicolin…………………………………………………….16
Methotrexate…………………………………………………...17
MEK ½ U0126…………………………………………………18
Collection of Cells for Luciferase and Protein Assay………………….18
Luciferase Assays………………………………………………19
Protein Assay…………………………………………………...19
Data Analysis…………………………………………………...20
Analysis of Potential Transcription Factor Binding Sites………………20
Transient Transfection of Dkk-1 Promoter Constructs…………………20
v
7
III. RESULTS…………………………………………………………………..23
Relative Expression Levels and Generation of cell lines for analysis
of Dkk-1 promoter activity…..………...…….…………………………23
Analysis of Dkk-1 expression under different growth conditions…….....23
Growing and Confluent Cells………………………………..26
Growing and Serum Starved…………………………………26
Activity of the Dkk-1 promoter during the cell cycle………..31
Effects of cell cycle and growth inhibitors
on Dkk-1 promoter activity…………..…………………………………33
MEK ½ U0126……………………………………………….36
Aphidicolin…………………………………………………..37
Methotrexate…………………………………………………40
Identification of Transcription factor binding sites………………….43
IV. DISCUSSION………………………………………………………..………47
Dkk-1 Promoter Activity Decreases in Serum Starved and Density
Arrested Cells……..……………………………………….……………49
Dkk-1 promoter Activity shows little variation during the Cell
Cycle……………………………………………………………………50
The Dkk-1 promoter Lacks Sensitivity to a Ras Pathway
Inhibitor…………………………………………………………………51
The Dkk-1 Promoter Does Not Respond to an Inhibitor of S Phase….....51
The Dkk-1 promoter is Sensitive to a Folate Pathway
Inhibitor…………………………………………………………………52
The Region between -1068 and -535 Appears to be Important for
Regulation of Dkk-1……………………………………………………53
Expression from the Control vector pGL3 Basic Varies………...............56
The Region between 1068 and 535 contains Multiple Binding Sites…....56
Experimental Concerns……………………………………………….….57
Summary…………………………………………………………………57
REFERENCES……………………………………………………………………….….59
vi
8
LIST OF TABLES
Page
Table 1 Identified Transcription Factor Binding Sites……………………………46
Table 2 Summary of Results………………………..………………………..…...48
vii
9
LIST OF FIGURES
Page
Figure 1 Wnt Signaling Pathway……………………………………...…………….6
Figure 2 Dkk-1 Upstream Promoter Region with
Transcription Factor Binding Sites…………………………………........12
Figure 3 Dkk-1 LUC deletion constructs…………………………………….……24
Figure 4 Transient Transfection of pGL3, 228Dkk-1 LUC, 535Dkk-1 LUC and
1068Dkk-1 LUC………………………..……………………………..…25
Figure 5A Promoter activity in Growing and Confluent Cell Populations in
535Dkk-1LUC and 1068Dkk-1LUC………………………………...…27
Figure 5B Promoter activity in Growing and Confluent Cell Populations in
228Dkk-1 LUC and pGL3 Basic……………………….……..………..28
.
Figure 6 Promoter activity in Growing and Serum Starved Cell Populations in
535Dkk-1 LUC and 1068Dkk-1LUC …………………..………….…..30
Figure 7 Promoter activity in Growing and Serum Starved Cell Populations in
228Dkk-1 LUC and pGL3 Basic………………………………..….…..32
Figure 8 Cell cycle Expression in 535Dkk-1 LUC and 1068Dkk-1……………....34
Figure 9 Cell cycle Expression in 228Dkk-1 LUC and pGL3 Basic……………...35
Figure 10 Promoter activity in 535Dkk-1 LUC and 1068Dkk-1LUC cells
treated with MEK 1/2 U0126……………………………..…………….38
Figure 11 Promoter activity in 228Dkk-1 LUC and pGL3 Basic cells
treated with MEK 1/2 U0126………….…………………………..........39
Figure 12 Promoter activity in 1068Dkk-1LUC cells treated with Aphidicolin …...41
Figure 13 Promoter activity in 535Dkk-1 LUC and 228Dkk-1 LUC
treated with Aphidicolin…………………….…………………….……42
.
Figure 14 Promoter activity in 535Dkk-1 LUC and 1068Dkk-1LUC cells
treated with Methotrexate………………………………………..…......44
viii
10
Figure 15 Promoter activity in 228Dkk-1 LUC and pGL3 Basic cells
treated with Methotrexate………………………………………………45
ix
1
CHAPTER I
INTRODUCTION
The mechanisms controlling cell proliferation and differentiation are of
fundamental importance. Significantly, knowledge of these mechanisms has broad
applications to human health, in particular cancer and stem cell therapeutics. The Wnt
signaling pathway is involved in cell fate and control of proliferation. The canonical Wnt
pathway is antagonized by Dickkopf-1 (Dkk-1), which prevents the formation of an
efficient Wnt receptor complex and thus has many consequences for the cell including
decreased Wnt signaling and the hindrance of Wnt induced transcriptional regulation.
This can affect cell growth, cell differentiation, and possibly lead to apoptosis or cell
death. Dkk-1 has been shown to be involved in mesenchymal and epithelial stem cell
proliferation and differentiation. It has also been shown that Dkk-1 can act as a tumor
suppressor. If Dkk-1 is absent then there is an increase in uncontrolled cell growth,
which can lead to tumor formation. The control of Dkk-1 expression is not completely
understood. This knowledge is important because Dkk-1 has a central role in modulating
the Wnt pathway and stem cell fate. In this study, the expression of the Dkk-1 gene
under different growth conditions will be analyzed. The region of the Dkk-1 promoter
required for its expression will then be determined. Potential transcription factor binding
sites will be identified within these regions using bioinformatic approaches. These sites
will eventually be mutated to determine if they are involved in Dkk-1 expression.
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Background
Regulation of Cell Growth and Division
The behavior of a cell is carefully regulated by the signals that it receives and
responds to from its environment. These signals are responsible for initiating
intracellular events such as metabolism, movement, proliferation, and differentiation.
Cell proliferation is dependent on the cell cycle, a highly regulated division cycle that
consists of four processes: cell growth, replication of DNA, distribution of chromosomes
to daughter cells, and cell division. A eukaryotic cell divides about every 24 hours. Its
cell cycle is divided into two parts: mitosis (nuclear division) and interphase (cell growth
and DNA replication). Interphase is the period between two mitosis stages and includes
G1, S and G2 phases. During G1 (gap 1) the cell is growing and preparing for replication
of DNA. G1 is followed by the S phase (synthesis) where DNA is replicated. G2 (gap 2)
is next where the cell continues to grow and proteins are made in preparation for mitosis.
The M phase (mitosis) corresponds to separation of the replicated chromosomes and is
usually followed by cytokinesis. There are four distinct phases of mitosis: prophase,
metaphase, anaphase and telophase.
The ability of a cell to progress between the stages of the cell cycle is controlled
by extracellular signals and internal signals responsible for coordinating the processes
that take place during the cell cycle. One of the central signaling pathways in controlling
cell proliferation is the Ras pathway. It is an intricate signaling cascade that plays an
important role in transmitting signals from growth factor receptors, regulating gene
expression, and preventing apoptosis (McCubrey et al, 2006). Activation of this pathway
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begins with the stimulation of growth factor receptors leading to the activation of Ras (a
small GTPase) (Cooper and Hausman, 2007). Ras interacts with the Raf protein kinase.
Raf phosphorylates MEK (MAP kinase/ERK kinase) and MEK phosphorylates ERK
(extracellular signal regulated kinase). Once ERK is phosphorylated it is responsible for
phosphorylating many other target proteins such as transcription factors and protein
kinases (Cooper and Hausman, 2007). Many studies have shown that the Ras pathway
becomes hyperactivated during human cancer development.
One important consequence of increased Ras signaling is upregulation of cyclin
D expression. Cyclin D protein then complexes with its partner, cyclin dependent kinase
(cdk) 4 or 6 which functions as a kinase, phosphorylating various substrates. Cyclin D-
cdk 4/6 activity eventually leads to passage from G1 phase into S phase. At this point the
cell is independent of growth factors and proceeds through the cell cycle and mitosis.
Progression through the cell cycle results from the sequential activity of different cyclin-
cdk kinases. In order of activity these are cyclin D-cdk 4/6 (G1), cyclin E-cdk 2 (G1/S),
cyclin A-cdk 2 (S), and cyclin B-cdk 1 (M).
The availability of growth factors in animal cells has an important role in the cell
proliferation processes such as growth, DNA replication and mitosis. The regulation of
these processes involves several checkpoints that control progression through the phases
of the cell cycle. If growth factors are not available during G1 then the cells enter G0, a
quiescent stage of the cell cycle. Most proliferation checkpoints are regulated in G1 and
along with regulating cell cycle progression they also are coordinated with one another to
ensure that the events of the cell cycle take place in a sequential order (McCubrey, 2006).
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The Wnt signaling pathway and Control of Cell Growth and Differentiation
Cell division within tissues of vertebrates is highly regulated and for the most
part, occurs within the undifferentiated stem cell populations. Those stem cells respond
to internal and external signals to tell them when to divide. One of the important
signaling pathways involved in controlling stem cells is the Wnt pathway. The canonical
Wnt pathway begins with the binding of Wnt ligands to the frizzled transmembrane
receptor and LPR 5 and 6, which are two single-transmembrane protein members of the
LDL receptor-related protein (LRP) family (Schweizer and Varmus, 2003) (Fig. 1A).
Once frizzled is activated, it recruits the cytoplasmic bridging molecule Disheveled,
which inhibits glycogen synthetase kinase 3 (Gregory et al, 2003). This inhibition
decreases phosphorylation of β-catenin thus preventing β-catenin from being degraded by
the ubiquitin pathway (Fig. 1A) (Kikucji, 2000; Huelsken and Birchmeier, 2001). β-
catenin then moves to the nucleus where it forms a complex with the transcription factors
leukocyte-enhancing factor (LEF-1) and T-cell factor (TCF-1), which then activates
transcription of target genes (Liu et al, 2003). These transcription factors promote
differentiation or proliferation (Liu et al, 2003). There are a large number of Wnt ligands
that function in different cell types and during development (Miller, 2001).
One example of the role of Wnt signaling and the control of cell division and
differentiation is in the intestinal epithelium. The Wnt signaling pathway is thought to
play a major role in controlling stem cell proliferation in the gut, namely the crypt cell
population (Crosnier at al, 2006). When the Wnt pathway is over activated by mutations
in components such as β-catenin and adenomatous polyposis coli (APC), the downstream
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targets of the pathway are activated. The crypts become enlarged and polyps form,
leading to some colorectal cancers. If the Wnt pathway allows cells to proliferate
indefinitely, a large number of cell cycles can result generating masses of giant crypt
cells. Therefore, regulating the Wnt pathway is important to prevent polyps from
growing without limit (Kuhnert et al, 2004).
Wnt signaling is also critical in mesenchymal differentiation and has been shown
to be involved in differentiation of skeletal and cardiac muscle, adipocytes, bone and
cartilage (Horowitz, 2004).
Dkk-1 Structure and Function
Dkk-1 is a secreted agonist of canonical Wnt signaling that interacts with Wnt
coreceptors (Gregory, 2003). In humans, Dkk-1 mRNA is 1681 base pairs in length and
codes for a 35 kDa protein (Kuhert et al, 2004). The binding of Dkk-1 to LPR-5/6 allows
for the disassociation of LPR-5/6 from frizzled and prevents the formation of an efficient
Wnt receptor complex (Gregory, 2003) (Fig. 1B). This in turn causes decreased Wnt
signaling, an unstable β-catenin molecule, and hinders Wnt-induced transcriptional
regulation (Gregory, 2003). This affects cell fate and cell growth and can lead to
apoptosis (Fedi et al, 1999; Grotewold and Ruther, 2002).
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Fig. 1 Wnt signaling pathway. A) Binding of Wnt ligands leads to stabilization of β-catenin,
which moves to the nucleus and functions as a transcription factor. B) Inhibition of the Wnt
pathway by Dkk-1. Dkk-1 binds to the LPR receptors and increases disassociation of the LPR
receptors from the frizzled receptor.
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Role of Dkk-1 in Cell Proliferation
Dkk-1 has been shown to be involved in human bone mesenchymal stem cell
proliferation (Gregory et al, 2003). Mesenchymal stem cells give rise to a wide variety of
cell types including cardiac muscle, fibroblasts (NIH3T3 cells), cartilage, bone, skeletal
muscle, fat, stroma, and brain tissue (Horwitz, 2004). Synthesis of Dkk-1 causes the cells
to re-enter the cell cycle by inhibiting the Wnt pathway. This was demonstrated using
human
mesenchymal cell (hMSC) lines cultured from the bone marrow of human donors. The
cell cycle was analyzed to determine the stages of cell growth and the effects of Dkk-1 on
proliferation. Initially, hMSC growth during early log phase was arrested after replacing
conditioned media with fresh media containing no Dkk-1. The addition of conditioned
media from rapidly dividing hMSCs increased cell division (Gregory et al 2003). The
level of secreted Dkk-1 protein was analyzed by methoinine labeling and shown to be
high in the conditioned medium. The results demonstrate that the cells do not leave an
extended log phase and reenter the cell cycle until they have synthesized Dkk-1 and the
level of Dkk-1 has accumulated in a significant amount in the culture media. This was
further proven by adding recombinant Dkk-1 to the hMSC cells in early log phase of
growth. Cells treated with Dkk-1 protein showed increased proliferation compared to
control without Dkk-1. As the hMSC cells moved from the log phase of cell growth to
the stationary phase of cell growth, the level of Dkk-1 was found to decrease and the
amount of Wnt-5A increased (Gregory et al, 2003).
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In contrast, Dkk-1 has also been found to function as a tumor suppressor. This
means that in the absence of Dkk-1 there is a lack of growth control and increased
tumorigenesis. This was shown in two studies. In the paper by Gonzales-Sancho et al
(2005), Dkk-1 expression was analyzed in 32 pairs of human colon tumors and in normal
tissues. RT-PCR analysis showed that Dkk-1 was downregulated in colon tumors when
compared to normal tissue. This decrease may in part, be due to inactivation of the Dkk-1
promoter by hypermethylation of the promoter (Aquilera et al, 2006). In another study,
Dkk-1 was isolated from non-tumorgenic revertants of HeLa cells as a gene that
increased in activity (Mikheev et al, 2004). In this study, overexpression of Dkk-1 was
shown to increase apoptosis but not to affect cell growth. Also, this effect did not involve
the canonical β-catenin pathway. These studies implicate Dkk-1 as a tumor suppressor.
Regulation of Dkk-1 gene expression
The Dkk-1 gene has been shown to be upregulated by β-catenin/TCF resulting in
a negative feedback loop. In one study, a region of the Dkk-1 promoter containing nine
binding sites for TCF was cloned to examine the regulation of Dkk-1 gene (Gonzales-
Sancho et al, 2005). The roles of various TCF sites were then examined by generating
deletion constructs made from the Dkk-1 promoter. The results showed that the TCF
sites close to the initiation site and in the –909/-822 region contributed most significantly
to the increase in Dkk-1 expression by activation of the Wnt pathway. The authors also
examined Wnt proteins that signal in non-canonical and canonical pathways and how
they induce the Dkk-1 promoter. They co-cultured cells that express Wnt-1 (canonical
β-catenin) or Wnt-5A (non-canonical) with cells transfected with the Dkk-1 promoter
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reporter construct. Co-culture with Wnt-1 led to the activation of Dkk-1 promoter but
Wnt-5A did not. When cells expressing Wnt-1 were co-transfected with a Dkk-1
expression vector the activity from the Dkk-1 promoter was reduced, thus Dkk-1 protein
can block transcription from its own promoter via negative feedback.
In another study, transcriptional targets of β-catenin were identified by
microarray analysis (Chamorro et al, 2005). Dkk-1 was identified as a gene to be strongly
induced. Further analysis showed, as in the study by Gonzales Sancho et al (2005), that
the Dkk-1 promoter contains TCF binding sites that are required for this response to β-
catenin activation. These studies provide strong support that Dkk-1 is upregulated by the
activation of β-catenin.
Dkk-1 was found to be upregulated by p53. p53 is a tumor suppressor and plays a
role in response to DNA damage and apoptosis. Messenger RNA from a cell line, p53-3,
that expresses p53 was assayed and cDNA fragments were isolated (Wang et al, 2000).
One clone was shown to be a derivative of the Dkk-1 gene. It was found that wild type
p53 induces Dkk-1 and the amount of Dkk-1 in cells expressing p53 was 6-8 times higher
than those cells not expressing p53 (Wang, 2000). Results also indicated that in cell
lineages with endogenous wild type p53, Dkk-1 is induced by DNA damage. To test this,
five cell lines were treated with camptothecin (a DNA damaging agent) and the levels of
Dkk-1 and p21 were analyzed (Wang, 2000). Three of the cell lines, which carried the
endogenous wild type p53 induced both Dkk-1 and p21. Dkk-1 was not induced in the
other two cell lines, which carried a mutant p53 gene. It was also necessary to determine
if Dkk-1 is regulated transcriptionally by p53. To do this the authors looked for a p53
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responsive element in the Dkk-1 DNA sequence. A 3.4 kb region in the Dkk-1 gene was
sequenced and a potential binding site for p53 was located 2.1 kb upstream from the Dkk-
1 transcription start site. This site was shown to bind p53 and allow for p53 activation of
a Dkk-1 luciferase reporter construct (Wang, 2000).
The Dkk-1 gene has also been shown to be induced by glucocorticoid (Ohnaka et
al, 2004). The addition of dexamethasone to human osteoblasts increased the expression
of Dkk-1 mRNA in a dose and time dependant manner. Dexamethasone also increased
the activity of the Dkk-1 promoter as assayed with the Dkk-1 luciferase reporter. Three
glucocorticoid response elements were identified in the Dkk-1 promoter between –837
and –314 base pair upstream (Ohnaka, 2004). More recently, Dkk-1 expression has been
shown to be increased by progesterone in human endometrial stromal cells (Tulac et al,
2006).
Other transcription factors shown to activate Dkk-1 include BMP-4 and c-Jun
(Grotewold and Ruther, 2002). In this study, these transcription factors upregulated Dkk-
1 in the normal developing embryo and in embryos subjected to ultraviolet radiation and
other genotoxic substances.
A diagram of the Dkk-1 upstream promoter region with the locations of characterized
transcription factor binding sites is shown in Fig. 2. Overall, the above studies suggest
that Dkk-1 is regulated by multiple factors under diverse conditions. However, the
factors involved in regulating Dkk-1 expression during cell growth are still not known.
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Project Goals and Overview
The goal of this study was to characterize the promoter of the Dkk-1 gene and
determine what region of the promoter is required for regulated expression of the Dkk-1
gene under different growth conditions. To do this, we first analyzed the activity
of the Dkk-1 gene under different growth conditions and during the cell cycle. The
hypothesis was that the activity of the Dkk-1 promoter will vary expanding cell
populations and low in confluent and serum starved, non-dividing cells depending on the
growth state of the cell population. Second, we wanted to determine the region of the
Dkk-1 promoter required for its activity under selected growth conditions. The hypothesis
for this goal was that there is a specific region in the promoter sequence where
transcription factors bind that are necessary for Dkk-1 activity under different growth
conditions. When this region is removed or modified, we believed there would be little
or no Dkk-1 activity, or a modified pattern of expression. Finally, we wanted to identify
the transcription factors involved in regulating the activity of the Dkk-1 promoter under
selective growth conditions. The hypothesis for this was that specific transcription
binding sites would be identified in the regions of the Dkk-1 sequences required for its
regulation. Mutation of those sites should alter expression of Dkk-1 under different
growth conditions.
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Human Dkk-1 Gene Upstream Region
2.5
TCF
2.0 1.5 1.0 0.5
p53 TCF
GRGR
GR TCF
TCF +1
A
B P53 AGcCAAGCTTttaatgAAcCAAGTTC -2148 to 2122
TCF CTTGAA
CTTTGTT
GR AGAACA
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CAGAG
Fig. 2Dkk-1geneupstreamregionwithTranscriptionFactor bindingsites. Bindingsites
for onlythosetranscriptionfactors that havebeencharacterizedareshown. TheDNA
sequences andpositions for the factors are indicatedbelowthediagram. Datawas derived
fromWanget al 2000(p53) Chamorroet al 2005(TCF) andOhnakaet a l2004 (GR)
Fig 2. Dkk-1 Upstream Pro oter Region with Transcription Factor Binding
Sites. Binding ites fo only those transcription facto s th t have been
characterized are shown. The DNA sequences and positions for the factors are
indicated below the diagram (B). Data was derived from Wang et al 2000
(p53), Chamorro et al 2005 (T Cell Factor), and Ohnaka et al 2004
(Glucocorticoid).
TCF= T cell factor
GR= Glucocorticoid
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CHAPTER II
MATERIALS AND METHODS
Cell culture
The mouse fibroblast cell line NIH3T3 was obtained from the American Type Culture
Collection (ATCC) and cells were cultured in DMEM-C at 37o Celsius in an incubator
containing 5% carbon dioxide and 95% air. DMEM-C medium contains 88.8% (v/v)
Dulbecco’s Modified Eagles Medium (DMEM) with 3.7g/L sodium bicarbonate and 3.57
g/L HEPES, 10% Fetal Bovine Serum, 1.0% (v/v) Penicillin/Streptomycin (10,000 IU/ml
and 10,000 µg/ml) and 0.1% (v/v) Amphotericin fungicide (250 µg/ml).
Preparation of Stable Cell lines
Dkk-1-luciferase plasmids (Dkk-1 LUC) containing 1068, 535, and 228 base pairs of
upstream sequence and 48 base pairs downstream of the +1 site were obtained from
Chamorro et al (2005). Stable lines of NIH3T3 mouse fibroblast cells were prepared
using the Calcium-Phosphate method. The Dkk-1 LUC vectors were mixed with the
neomycin (G418) selection vector (pMC1neopolyA; Stratagene) at a ratio of 4:1,
respectively. The DNA was precipitated together by making the solution 0.2 M NaCl and
adding two volumes of cold 95% ethanol and placing the samples at –20 o Celsius. The
co-precipitated Dkk-1 LUC/neo DNA was pelleted and taken up in 100 µL of sterile
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water at a concentration of 0.5 µg/µL. The NIH3T3 mouse fibroblast cells were
collected and re-plated for transfection in 100 mm plates at 2x105 cells per plate. The
Dkk-1 LUC/neo DNA was transfected using the Calcium-Phosphate Profection Kit
(Promega). Essentially, 10 µL (10 µg) of Dkk-1 LUC+neo was mixed with the 5M CaCl2
solution and the mixture added to 2x HEPES buffer while vortexing. The sample was
incubated at room temperature for 30 minutes and then added dropwise to the cells. The
next day, the medium was changed to fresh DMEM-C. Three days after transfection, 25
µL of G418 (200 mg/mL) was added to each plate of cells to give a final concentration of
0.5 mg/mL. Selection continued until all of the cells lacking the neo-selection vector
were killed and colonies began to form. During this period, fresh medium was added
every three days along with G418. The resistant cells were collected by trypsinization
and re-plated in T-75 flasks. Stocks of resistant cells were stored in liquid nitrogen. For
storage, cells were collected and resuspended in DMEM-C and mixed 1:1 with 10%
dimethyl sulfoxide in DMEM-C. These cells were transferred to freezing tubes and
frozen for 24 hours at -70o Celsius before transferring them to liquid nitrogen.
Collection of Cells for Promoter Analysis Studies
Typically stably transfected Dkk-1 LUC cells were plated on a Friday for
experiments the following week. Frozen stocks were plated in 12 mL of DMEM-C in a
T-75 flask to which 10 µL of G418 (200mg/mL) was added. On Monday, the cells were
collected and re-plated in the appropriate culture plate. To collect the cells, they were
first washed with 4 mL of sterile Phosphate Buffered Saline (PBS). The PBS was
removed and 4 mL of 1x Trypsin-EDTA (0.05%; 0.53 mM) was added to the flask. After
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about one minute the cells were observed under a microscope to ensure that they had
come off of the flask. An equal volume of DMEM-C was added and the entire contents
of the flask were transferred to a 15 mL Falcon tube. The tubes were spun in a clinical
centrifuge at setting #3 (1080 RPM) for 5 minutes. The supernant was removed and the
pelleted cells were taken up in 5 mL of DMEM-C. The cells were counted using a
hemacytometer and the appropriate cell density was plated for each experiment and
culture plate.
Growing and Confluent Cell Populations
On the first day, collected 1068Dkk-1 LUC, 535Dkk-1 LUC, and 228Dkk-1
LUC-NIH3T3 cells were plated in DMEM-C in a 24 well culture dish at a density of
4x104 cells per well. On the next day, the medium was changed to fresh DMEM-C. Cell
lysates were collected from four wells, representing Day 1. Each day for the next four
days, the medium was changed and the cell lysates were collected. The cells were
assayed for luciferase activity and the protein concentration of the lysate determined. A
cell line containing pGL3-Basic, the luciferase vector without a promoter, was used as a
control.
Serum Starved and a Growing Population
On the first day, 1068Dkk-1 LUC, 535Dkk-1 LUC, and 228Dkk-1 LUC-NIH3T3
cells were plated in DMEM-C in two 24 well culture dishes at a density of 4x104 cells per
well. On the next day, the medium was changed in one plate (designated Low Serum) to
DMEM-0.5% Fetal Bovine Serum and in the other plate to fresh DMEM-C. Cell lysates
were collected from three wells of each plate (designated Day 1). Each day for the next
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four days, the medium was changed to DMEM-C or Low Serum DMEM and the cell
lysates were collected. The cells were assayed for luciferase activity and the protein
concentration of the lysate determined. A cell line containing pGL3-Basic, the luciferase
vector without a promoter, was used as a control.
Cell Cycle Analysis
On the first day, 1068Dkk-1 LUC, 535Dkk-1 LUC, and 228Dkk-1 LUC-NIH3T3
cells were plated in DMEM-C in a 24-well culture dish at a density of 4x104 cells per
well. On the next day, the medium was changed to DMEM-0.5% Fetal Bovine Serum
(Low serum) to serum starved the cells for a period of 60-72 hours. After this period, the
cells were released back into the cell cycle by changing the medium to DMEM-C
containing 10% FBS. Cell lysates were collected beginning at 9 AM and then every 6
hours for 30 hours. The cells were assayed for luciferase activity and the protein
concentration of the lysate determined. A cell line containing pGL3-Basic, the luciferase
vector without a promoter, was used as a control.
Treatment with Inhibitors
Aphidicolin
On the first day, 1068Dkk-1 LUC, 535Dkk-1 LUC, and 228Dkk-1 LUC-NIH3T3
cells were plated in a 24-well culture dish in DMEM-C at a density of 6x104 cells per
well. The next day, the cells were treated with the DNA ploymerase inhibitor
Aphidicolin (Calbiochem) from a 1 mg/mL stock in dimethyl sulfoxide (DMSO). To
make a 1:4 dilution, 5 µL of stock was added to 15 µL of DMSO in a sterile microfuge
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tube. The cells were treated with 0 µM, 0.5 µM and 2 µM aphidicolin for 24 and 48
hours. To the cells treated with 0 µM, 2 µL of DMSO was added, 2 µL of the 1:4
dilution was added to cells treated with 0.5 µM, and 2 µL of the stock solution was added
to the cells treated at 2 µM. Twenty-four hours later, half of the cells were collected and
the lysates stored at -20o Celsius. The next day, the remainder of the cells were collected
and stored at -20o Celsius in microfuge tubes. The cell lysates were assayed for
luciferase activity and the protein concentration of the lysates determined. A cell line
containing pGL3-Basic, the luciferase vector without a promoter, was used as a control.
Methotrexate
On the first day, 1068Dkk-1 LUC, 535Dkk-1 LUC, and 228Dkk-1 LUC-NIH3T3
cells were plated in two 24-well culture dishes in DMEM-C at a density of 6x104 cells per
well. The next day, the cells were treated Methotrexate (Fluka) from a 600 µM stock.
To make a 600 µM stock solution, 2.37 mg of methotrexate was mixed with 2 mL of
water. Five µL of 5N NaOH was added to bring the methotrexate into solution. The
solution was brought up to 10 mL with water and it was filter sterilized. The cells were
treated at concentrations of 0 µM (control), 1 µM, 10 µM, 20 µM, 50 µM, and 100 µM of
Methotrexate by addidng 0 µL, 0.83 µL, 16.6 µL, 41.5 µL, and 83 µL of the 600 µM
methotrexate stock to the appropriate wells. Incubation was for 24 and 48 hours. The next
day, the cells in one of the plates were collected and the lysates were placed in microfuge
tubes and stored at -20o Celsius. The following day, the cells from the remaining plate
were collected, placed in microfuge tubes, and stored at -20o Celsius. The cell lysates
were assayed for luciferase activity and the protein concentration of the lysate
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determined. A cell line containing pGL3-Basic, the luciferase vector without a promoter,
was used as a control.
MEK 1/2 Inhibitor, U0126
On the first day, 1068Dkk-1 LUC, 535Dkk-1 LUC, and 228Dkk-1 LUC-NIH3T3
cells were plated in a 24-well culture dish in DMEM-C at a density of 6x104 cells per
well. The next day, the cells were treated with the inhibitor MEK 1/2 U0126 (Promega).
To the vial of U0126, 234 µL of DMSO was added to make a 10 µM stock (A stock). To
make a 1:5 dilution, 40 µL of A was added to 160 µL of DMSO in a sterile microfuge
tube (B stock). The cells were treated at concentrations of 0µM (control), 10 µM, and 50
µM. To the control, 2.5µL of DMSO was added, 2.5 µL of B stock was added to cells
treated at 10 µM, and 2.5 µL of the A stock was added to the cells treated at 50 µM. The
next day, half of the cells were collected and the lysates were placed in microfuge tubes
and stored at -20o Celsius. The following day, the remaining cell lysates were collected,
placed in microfuge tubes, and stored at -20o Celsius. The cells were assayed for
luciferase activity and the protein concentration of the lysate determined. A cell line
containing pGL3-Basic, the luciferase vector without a promoter, was used as a control.
Collection of Cells for Luciferase and Protein Assay
To collect the cells in preparation for luciferase assay, the medium was removed
from each of the wells in the dish. Five hundred microliters of PBS was added to each
and then removed by vacuum suction. One hundred and fifty microliters of 1x Reporter
Lysis Buffer (Promega) was added to the cells and incubated at 37 o Celsius for 15
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minutes. After incubation, the cell lysates were collected from the wells, placed in
labeled microfuge tubes, and stored at -20 o Celsius.
Luciferase assays
Cells were assayed for luciferase activity using a Berthold luminometer (Lumat
LB9501). Relative light units (RLUs) of luciferase activity were determined by placing
30µL of cell lysate in a tube. After inserting the tube into the luminometer, the arm was
lowered to automatically inject luciferase substrate (luciferin) solution (Promega). The
sample was read for 10 seconds. The activity levels were expressed as RLUs per µg
protein.
Protein Assay
The level of protein was measured using a Bradford colormetric assay (BioRad).
A standard curve was prepared using 1 mg/mL bovine serum albumin (BSA) as the
standard. Six microfuge tubes were labeled. To the first microfuge tube, 800 µL of water
were added. To the next, 1 µL of BSA (1 µg) was added to 799 µL of water. The third
tube contained 5 µL (5 µg) of BSA and 795 µL of water. The fourth tube contained 10
µL of BSA (10 µg) and 790 µL of water. The fifth tube contained 15 µL of BSA (15 µg)
and 785 µL of water. The last tube contained 20 µL of BSA (20 µg) and 780 µL of
water. 200 µL of Bradford dye was added and each tube was vortexed. To prepare the
samples, additional tubes were labeled and 780 µL of water was added to the sample
tubes, along with 20 µL of the cell lysate and 200 µL of Bradford dye. Each tube was
vortexed. The contents of each tube were transferred into spectrophotometer cuvettes.
The standards and samples were read at 595 nanometers. A graph of the standard curve
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was made using a hand held calculator and the amount of protein in each sample was
extrapolated from the standard graph.
Data Analysis
The raw values of RLU’s and µg protein were entered into Microsoft Excel 2003.
The RLU/µg of protein was calculated and the four replicas were averaged. A graph was
made using the average. Error bars indicate the standard error, which was calculated by
taking the standard deviation divided by the square root of n (where n=number of
replicas; which in most cases was 4).
Analysis of Potential Transcription Factor Binding Sites
First, the upstream sequences (2500 bp) of the Dkk-1 promoter were found using
the UC-Santa Cruz website (http://genome.ucsc.edu/). Accessing the Dkk-1 Ref Seq gene
was accomplished using the Accession number NM_012242. The sequence region from
–1068 to –535 upstream from the +1 start site was copied and pasted into the Patch site
(http://www.gene-regulation.com/pub/programs.html#match) for identification of
potential transcription factor binding sites. The search conditions were set at 2
mismatches, no less than 5 nucleotide binding sites, and a lower score boundary of 87.5.
Transient Transfection of Dkk-1 Promoter Constructs
NIH3T3 cells were transfected with plasmid DNA using the TransIT-3T3
Transfection Kit (Mirus). NIH3T3 cells were plated in a 24-well dish at a density of
1.5x105 cells per well in DMEM- C. The next day, the cells were transfected with the
plasmid DNA. First, 50 µL of serum free medium and 1.5 µl of TransIT –3T3
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Transfection Reagent was added to 12 sterile microfuge tubes and the contents were
mixed. 0.5 µg of the 4 plasmid DNA constructs (pGL3, 228, 535, and 1068) was added
to each of 3 tubes and mixed. 1 µL (10 ng) of SV40-Renilla luciferase reporter plasmid
(Promega) was added to each tube and mixed. 0.5 µL of Authority Reagent was added
and the tubes were incubated at room temperature for 30 minutes. After incubation, the
TransIT –3T3 Transfection Reagent/DNA/3T3 Authority Reagent mixture was added to
the cells dropwise. The dish was rocked back and forth to distribute the complexes
evenly. The cells were incubated for 48 hours.
The cells were collected as previously described. To assay the cells, Renilla
Luciferase Assay Reagent was prepared (Promega) by adding 10 µL of Renilla substrate
to 1 mL of Renilla Luciferase Assay buffer. The assay was performed in a Berthold
luminometer (Lumat LB9501). Relative light units (RLUs) of Renilla activity were
determined by placing 30µL of cell lysate in a tube. After inserting the tube into the
luminometer, the arm was lowered to automatically inject Renilla substrate. The sample
was read for 10 seconds. The cell lysates were then assayed for luciferase activity using
luciferase substrate (luciferin) solution (Promega). Relative light units (RLUs) of
luciferase activity were determined by placing 30µL of cell lysate in a tube. After
inserting the tube into the luminometer, the arm was lowered to automatically inject
luciferase substrate solution. The sample was read for 10 seconds. The activity levels for
each construct (pGL3, 228, 535, and 1068) were expressed as Beatle RLU/ Renilla RLU.
The raw values of Beatle and Luciferase RLU’s were entered into Microsoft Excel 2003.
The Beatle RLU/Renilla RLU was calculated and the 3 replicas were averaged. A graph
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was made using the average. Error bars indicate the standard error, which was calculated
by taking the standard deviation divided by the square root of n (where n=number of
replicas).
23
CHAPTER III
RESULTS
Relative Expression Levels and Generation of cell lines for analysis of Dkk-1 promoter
activity
Three Dkk-1 luciferase reporter vectors were obtained from Chamarro et al
(2005). These contained 228 base pair, 535 base pair and 1068 base pair of upstream
sequence plus 43 base pair of sequence downstream of the transcription start site (Fig. 3).
These constructs were transfected into NIH3T3 cells along with a neo-poly A selection
vector and selected with G418 to generate stable lines. The resulting resistant clones
were collected as a group. The luciferase reporter vector pGL3-Basic was also stably
transfected as a control. The relative levels of promoter activity from the plasmids were
measured by transient transfection. Activity was normalized to Renilla luciferase activity
from a co-transfected SV40-Renilla luciferase vector. As shown in Fig. 4, the activity
from the 228Dkk-1 LUC construct is greater than the 535 construct but not significantly
different from the 1068 construct.
Analysis of Dkk-1 expression under different growth conditions
Dkk-1 mRNA levels have been shown to vary in mesenchymal stem cell populations
(Gregory et al, 2003). In expanding cell populations, Dkk-1 mRNA levels are high and
the levels decrease in non-dividing confluent cells. Moreover, Dkk-1 mRNA levels
decrease in serum starved cells (Gregory et al, 2005). In these studies, the activity
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Fig. 3 Dkk-1 LUC deletion constructs. Three
reporter vectors containing 1068, 535, and
228 bp of upstream sequence and 43 bp of
sequence downstream of the transcription start
site were obtained from Chammaro et al 2005.
The location of characterized transcription
factor binding sites glucocorticoid (GR, not
shaded) and T cell factor (TCF, shaded) are
shown.
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Fig. 4 Transient Transfection of pGL3, 228Dkk-1 LUC, 535Dkk-1 LUC, and
1068Dkk-1 LUC. The cells were transiently transfected with each of the
constructs and a SU40-Renilla luciferase control vector. Two days after
transfection cells were collected and assayed for firefly and Renilla luciferase.
The activity is expressed as Beatle RLU/Renilla RLU. The error bars represent
the mean +/- standard error (n=3).
26
of the promoter was analyzed under different growth conditions. These included growing
and confluent cells, normal and serum starved cells and different stages of the cell cycle.
Growing and Confluent Cells
Each of the NIH3T3 cell lines (1068, 535, 228, and pGL3) was plated in 24-well
dishes at subconfluent density. The cells were allowed to grow for five days and the
media was changed each day. The cells were collected each day at the same time. The
luciferase activity and protein were determined as described and the promoter activity
was expressed in relative light units per microgram of protein (RLU/µg protein).
The 1068Dkk-1 LUC cells had an activity level that increased up to Day 3 and
then decreased from Day 3 to 5 (Fig. 5A). The pattern of Dkk-1 promoter activity in the
535 cell line was distinct (Fig 5A). The activity increased steadily throughout all five
days. For the 228Dkk-1 LUC construct, the promoter activity increased at Days 1
through 3. There was a decrease in promoter activity from Day 3 to 5 (Fig 5B). Activity
in the pGL3 control cell line increased at Days 1 through 4 (Fig 5B). At Day 5 the
promoter activity decreases. Visual examination of the cells confirmed that the cells were
confluent by Day 5 in all cell lines. These experiments were repeated one time with
similar results.
Growing and Serum Starved
The stably transfected NIH3T3 cells (pGL3, 228, 535, and 1068) were plated in
24-well dishes at a sub-confluent density. The next day, the medium was changed in half
of the wells to low serum. The medium was also changed in the other wells (complete
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Fig. 5A Promoter activity in Growing and Confluent Cell Populations in
535Dkk-1LUC and 1068Dkk-1 LUC. Cells stably transfected with the
indicated Dkk-1 luciferase reporter vectors were plated and allowed to
grow over the days indicated. The lysates were collected each day for 5
days and assayed for luciferase (RLU) and total protein determined. The
activity is expressed as RLU per µg of protein. The error bars represent the
mean +/- standard error (n=4).
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Fig. 5B Promoter activity in Growing and Confluent Cell Populations in
228Dkk-1 LUC and pGL3 Basic. Cells stably transfected with the indicated
Dkk-1 luciferase reporter vectors were plated and allowed to grow over the days
indicated. The lysates were collected each day for 5 days and assayed for
luciferase (RLU) and total protein determined. The activity is expressed as RLU
per µg of protein. The error bars represent the mean +/- standard error (n=4).
Error bars for the 228Dkk-1 LUC are within the limits of the squares.
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medium). Each day of collection, the medium was changed in both the low serum and
complete medium wells. The cells were collected on Day 1 (day after
replating), 2 and 3 in luciferase lysis buffer and relative light units (RLU) and total
protein determined as described. Promoter activity was expressed as RLU/µg protein.
Figure 6 shows the promoter activity of the 1068-Dkk-1 LUC construct. The cells
grown in low serum show an increase in promoter activity between Days 1 and 2.
However, after Day 2, there is a significant decrease. The cells grown in normal serum
show a steady and significant increase in activity over all three days. At Day 3 the level
of activity in the cells grown in normal serum was more than 4 fold greater than the cells
at low serum.
The 535-Dkk-1 LUC construct displayed a distinct and unexpected pattern of
promoter activity in cells grown in low and normal serum (Fig. 6). The cells grown in
low serum have a higher level of activity than those grown in normal serum with more
than a two fold increase in activity. On Day 1, the level of activity is low and identical for
both the serum starved and normal serum samples. However, cells grown in normal
serum have very little increase in activity between days 1 and 2. There is an increase in
activity between Days 2 and 3. At Day 3, the activity in low serum cells was 5 fold
greater than that in normal cells. These results were confirmed in an independently
conducted experiment.
Promoter activity in the 228-Dkk-1 LUC NIH3T3 cells increased over the three
days for cells grown in normal and low serum medium (Fig. 7). However, the level of
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Fig. 6 Promoter activity in Growing and Serum Starved Cell Populations in the
535Dkk-1 LUC and 1068Dkk-1 LUC. Cells stably transfected with the indicated Dkk-
1 Luciferase reporter vector were plated and allowed to grow. At Day 1, the medium
was removed and DMEM+0.5% FBS was added (serum starved) in one plate and
fresh DMEM-C was added to the other plate (growing population). Cells were
collected for 3 days and the lysates assayed for luciferase (RLU) and total protein
determined. The error bars represent the mean +/- standard error (n=4). The activity is
expressed as RLU per µg of protein. The dark diamond lines are normal serum and
light squared lines are low serum.
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activity in the low serum cells was less by 2 fold for Days 2 and 3, compared to the cells
grown in normal medium.
Figure 7 also shows the promoter activity of the pGL3-Basic plasmid (control)
over three days for growing and serum starved cells. On Day 1, the level of activity is
low and almost identical for both the serum starved and normal serum samples, as would
be expected. However, the cells grown in low serum have a significant increase in
promoter activity by Day 2 (more than two-fold), which steadily increases until Day 3.
The cells grown in normal serum also have in increase in promoter activity over all three
days nearly identical to the cells grown in low serum.
These experiments were repeated once and similar results were obtained. The
expression pattern for 1068 is as would be expected if Dkk-1 promoter activity
corresponds to published data on Dkk-1 mRNA levels (Gregory et al, 2003); that is
activity decreases in non dividing (serum starved) cells. The expression patterns for 535
and 228 are distinctly different in that promoter activity continues to increase rather than
decrease with serum starvation. These results suggest that a region of the Dkk-1
promoter between 1068 and 535 contains DNA sequences required for regulating Dkk-1
transcription in growing and non-growing, serum starved cells.
Activity of the Dkk-1 Promoter during the Cell Cycle
Published data, as previously described, suggest that regulation of Dkk-1 gene
expression is linked to the growth state of the cell population (Gregory, 2005). Indeed,
our results show that expression from the full length (1068) Dkk-1 vector is lower in
serum starved and confluent cells than in a growing population. We also wanted to
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Fig. 7. Promoter activity in Growing and Serum Starved Cell Populations in 228Dkk-1
LUC and pGL3 Basic. Cells stably transfected with the indicated Dkk-1 Luciferase
reporter vector were plated and allowed to grow. At Day 1, the medium was removed and
DMEM+0.5% FBS was added (serum starved) in one plate and fresh DMEM-C was
added to the other plate (growing population). Cells were collected for 3 days and the
lysates assayed for luciferase (RLU) and total protein determined. The error bars represent
the mean +/- standard error (n=4). The activity is expressed as RLU per µg of protein. The
dark diamond lines are normal serum and light squared lines are low serum.
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determine if Dkk-1 promoter activity varies during the cell cycle. To accomplish this
goal the cell cycle pattern of Dkk-1 promoter activity was analyzed in the NIH3T3 cells
with the stably transfected 1068, 535, and 228 reporter constructs. The stably transfected
NIH3T3 cells (pGL3, 228, 535, and 1068) were plated in multi-well dishes and on the
next day, the medium was changed to low serum. The cells were serum starved and then
released back into the cell cycle by changing the medium to complete medium.
The 1068Dkk-1 LUC shows a distinct pattern (Fig. 8). The promoter activity
displays a slight decrease from 0 hour to 24 hour, but is essentially flat. At hour 30 there
is almost a 3-fold increase in promoter activity. This could indicate that the cells have
completed a full cycle and have divided. It is not clear why such an increase was not
detected in the other cell lines. Figure 8 also shows the promoter activity in the 535Dkk-1
LUC. Activity is highest at 0 hour and then the activity steadily decreases throughout the
rest of the time course. The 228Dkk-1 LUC results are shown in Fig. 9. At hour 0, the
level of activity is highest and then decreases. After 18 hour activity remains essentially
flat. Figure 9 shows the promoter activity in the pGL3-Basic plasmid (control). The
level of activity begins high at hour 0. It then decreases from 0 hour to18 hour and then
slightly increases at 24 hour and remains essentially the same at 30 hour. Overall, these
results indicate that there is little or no cell cycle regulation of Dkk-1 promoter activity.
Effects of cell cycle and growth inhibitors on Dkk-1 promoter activity
Cell populations respond to various external and internal signals that lead to cell
division, withdrawal from the cell cycle, or possibly cell death. These signals include
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Fig. 8 Cell cycle Expression in 535Dkk-1 LUC and 1068Dkk-1. NIH3T3 cells
stably transfected with the 535Dkk-1 LUC and 1068Dkk-1 vector were plated
and serum starved. At time 0, the medium was removed and complete DMEM-
C was added. Cells were collected at the times indicated and the lysates were
assayed for luciferase (RLU) and the total protein determined. The promoter
activity is expressed as RLU per µg of protein. The error bars represent the mean
+/- standard error (n=4).
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Fig. 9 Cell cycle Expression in 228Dkk-1 LUC and pGL3 Basic. Cells stably
transfected with the pGL3 and 228Dkk-1 LUC vector were plated and serum
starved. At time 0, the medium was removed and complete DMEM-C was
added. Cells were collected at the times indicated and the lysates were assayed
for luciferase (RLU) and the total protein determined. The promoter activity is
expressed as RLU per µg of protein. The error bars represent the mean +/-
standard error (n=4).
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various growth factors that are secreted by the cells, found in the serum, or arise from
contact between individual cells. Our results indicate that the Dkk-1 promoter is
sensitive to cell density and growth factors in the medium. However, it does not appear
that Dkk-1 promoter activity is regulated during the cell cycle. In these studies, we asked
if inhibitors of the cell cycle and cell growth affect Dkk-1 promoter activity. The three
inhibitors used were the U0126, methotrexate, and aphidicolin. MEK 1/2 U0126 inhibits
the kinase activity of MAP kinase kinase, MEK. It inhibits active and inactive MEK 1/2
and is responsible for downstream inhibition of ERK 1 and ERK 2 mediated responses.
This inhibitor was used as a means to determine if the decrease in Dkk-1 promoter
activity was linked to the Ras pathway. The rationale is that removal of serum causes a
reduction in promoter activity, which is due to removal of Ras specific growth factors.
Methotrexate inhibits the enzyme dihydrofolate reductase (DHFR), a critical enzyme in
the folate pathway. Consequently, methtrexate treated cells are arrested in the S phase,
due to lack of thymidine for DNA synthesis. This inhibitor was selected, in part, because
previous studies have shown that Dkk-1 mRNA levels are reduced in folate deficient and
methotrexate treated cells. Aphidicolin arrests cells in G1 by blocking DNA synthesis and
inhibiting DNA polymerase α. We wanted to determine if stopping the cells at another
point in the cell cycle other than G0/G1 would alter Dkk-1 promoter activity.
MEK 1/2 Inhibitor U0126
The stably transfected NIH3T3 cells (pGL3, 228, 535, and 1068) were plated in
multi-well dishes. The next day, the cells were treated with U0126 at specified
concentrations. The cell lysates were collected 24 and 48 hours after treatment. Figure
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10 shows the 1068-Dkk-1 LUC construct. There was no distinct pattern of activity. At
24 hours after treatment there was a slight increase in promoter activity at 10 µg and a
slight decrease at 50 µg. At 48 hours, there was about the same level of activity at 0 µg
and 50 µg, but an increase in promoter activity in cells treated with 10 µg of U0126.
Figure 10 also shows the 535-Dkk-1 LUC construct. At 24 hours, there is almost a 3-fold
increase in promoter activity at 10 µg and 50 µg. The increase in promoter activity
continues at 48 hour at both 10 µg and 50 µg. The 228-DKK-1 LUC construct is shown
in Fig 11. Here, the activity increases as the concentration of U0126 increases both at 24
and 48 hours, however at 48 hour, there is a greater increase in promoter activity 50 µg.
Figure 11 shows the promoter activity in the pGL3 Basic plasmid at 24 and 48 hours after
treatment with MEK 1/2 U0126. At 24 hours, there is a decrease in activity in cells
treated with 10 µg and 50 µg of U0126. At 48 hours, there is no significant decrease in
promoter activity.
Aphidicolin
The stably transfected NIH3T3 cells (228, 535, and 1068) were plated in multi-
well dishes and the next day, the cells were treated with aphidicolin at specified
concentrations. The cell lysates were collected 24 and 48 hours after treatment. The
relative light units (RLU) and total protein were determined as described. The 1068-
Dkk-1 LUC construct is shown in Fig 12. At both 24 and 48 hours, there was essentially
no difference between the control treated cells at both concentrations.
38
0
2000
4000
6000
8000
10000
12000
14000
16000
24 hr 48 hr
R
L
U
/ µ
g
p
ro
te
in
0
5000
10000
15000
20000
25000
30000
24 hr 48 hr
R
L
U
/ µ
g
p
ro
te
in
Fig. 10 Promoter activity in the 535Dkk-1 LUC and 1068Dkk-1 LUC cells
treated with MEK 1/2 U0126. The cells were treated with U0126 at the indicated
concentrations and collected 24 and 48 hours after treatment. The cell lysates
were assayed for luciferase (RLU) and total protein determined. The promoter
activity is expressed as RLU per µg of protein. The error bars represent the mean
+/- standard error (n=4).
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Fig.11 Promoter activity in 228Dkk-1 LUC and pGL3-Basic cells treated with
MEK 1/2 U0126. The cells were treated with U0126 at the indicated
concentrations and collected 24 and 48 hours after treatment. The cell lysates were
assayed for luciferase (RLU) and total protein determined. The promoter activity
is expressed as RLU per µg of protein. The error bars represent the mean +/-
standard error (n=4).
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The decrease in overall promoter activity at 48 hour relative to the 24 hour is likely due
to the cells becoming confluent. Figure 13 shows the promoter activity in the 535Dkk-1
LUC construct. At 24 hours, the activity was about the same at all concentrations. At 48
hours the activity at 0.5 µg was about the same as the control, but a nearly 2-fold
decrease in activity was detected at 2 µg. The promoter activity of the 228Dkk-1 LUC
construct is shown in Fig. 13. At 24 hours, the promoter activity increased as the
concentration of aphidicolin increased. At 48 hours, the promoter activity decreased as
the concentration increased, with the decrease being almost 2 fold.
Methotrexate
The stably transfected NIH3T3 cells (pGL3, 228, 535, and 1068) were plated in
multi-well dishes and treated with methotrexate at specified concentrations for 24 and 48
hours. The cell lysates were collected at 24 and 48 hours after treatment. Overall the
responses of the different constructs to methotrexate treatment are distinct. The promoter
activity in the 1068-Dkk-1 LUC is shown in Fig. 14. After 24 hours of treatment, there
was essentially no difference between the control and treated cells. However, at 48-hour
promoter activity decreases to approximately the same level at all methotrexate
concentrations relative to the control, untreated cells. Figure 14 shows the 535Dkk-1
LUC construct. At 24 hours, the activity is about the same except at 100 µg. At this
concentration, there is a decrease in promoter activity to almost 3-fold.
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Fig. 12 Promoter activity in1068Dkk-1 LUC cells treated with Aphidicolin. The
cells were treated with aphidicolin at the indicated concentrations and collected 24
and 48 hours after treatment. The cell lysates were assayed for luciferase (RLU) and
total protein determined. The promoter activity is expressed as RLU per µg of
protein. The error bars represent the mean +/- standard error (n=4).
Aphidicolin
1068
24 hr 48 hr
Concentration (µg)
42
0
50
100
150
200
250
24 48
Concentration (µg)
R
L
U
/ µ
g
p
ro
te
in
0
2000
4000
6000
8000
10000
12000
24 48
R
L
U
/ µ
g
p
ro
te
in
Fig. 13 Promoter activity in 535Dkk-1 LUC and 228Dkk-1 LUC treated with
Aphidicolin. The cells were treated with aphidicolin at the indicated
concentrations and collected 24 and 48 hours after treatment. The cell lysates
were assayed for luciferase (RLU) and total protein determined. The promoter
activity is expressed as RLU per µg of protein. The error bars represent the mean
+/- standard error (n=4).
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At 48 hours promoter activity increases with increasing methotrexate concentration,
being significantly higher at 20, 50, and 100µg. Overall, at 48 hours there was an
approximately 2-3-fold increase in promoter activity. In Fig. 15 the 228Dkk-1 LUC
construct is shown. There is no significant difference between the untreated control and
treated cells at both 24 and 48 hour. The pGL3 Basic plasmid (Fig. 15) displays a
decrease in activity as the concentration of methotrexate increased in the 24 hour treated
cells. At 48 hours, there is no difference between the treated and untreated controls.
Identification of Transcription Factor Binding Sites
We wanted to analyze -1068 to -535 region of the Dkk-1 promoter to determine if
there were any transcription factors that could be involved in regulating the activity of
the Dkk-1 promoter under selective growth conditions. Using the UC-Santa Cruz website
(http://genome.ucsc.edu/) we were able to access the Dkk-1 Ref Seq gene region from –
1068 to –535 upstream from the +1 start site. This region was pasted into the Patch site
(http://www.gene-regulation.com/pub/programs.html#match) for identification of
potential transcription factor binding sites. Our search resulted in the identification of
several transcription factor binding sites (Table 1).
44
0
500
1000
1500
2000
2500
3000
3500
4000
4500
24 48
R
L
U
/ µ
g
p
ro
te
in
0
5000
10000
15000
20000
25000
30000
24 48
R
L
U
/ µ
g
p
ro
te
in
Fig. 14 Promoter activity in 535Dkk-1 LUC and 1068Dkk-1 LUC cells
treated with Methotrexate. The cells were treated with methotrexate inhibitor
at indicated concentrations and collected 24 and 48 hours after treatment.
The cell lysates were assayed for luciferase (RLU) and total protein
determined. The promoter activity is expressed as RLU per µg of protein.
The error bars represent the mean +/- standard error (n=4).
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Fig. 15 Promoter activity in 228Dkk-1 LUC and pGL3-Basic cells treated with
Methotrexate. The cells were treated with methotrexate at indicated
concentrations and collected 24 and 48 hours after treatment. The cell lysates
were assayed for luciferase (RLU) and total protein determined. The promoter
activity is expressed as RLU per µg of protein. The error bars represent the
mean +/- standard error (n=4).
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Table 1 Identified Transcription Factor Binding Sites *
Factor Binding site General feature
SF-1 
 
LUN-1 
 
c-Myb
SP-1 
 
NF-AT4
NF-κ B
POU2F1
WT-1 
 
AP-2 α A, B
YY1
TCF-4 
 
LEF-1 
 
TFIID
Elk-1 
TCAAGGTAA
TGGGA, TCCCA
CAGTTG, CAGTTG, CAACTG,
CAACT
CCCCC; CCCCTCCCC
GGAAA
GAAATTTCC
TATGCAAAT
CGCCCTCTC
GGGAAGA
CATTT
CTTTGAA; TTCAAAG;
TTGAA; CTTTGAT
ATCAAAGTA; ATCAAAG
TATAT
TTCCGA
Steroidogenesis; male sexual
differentiation
Expressed in lung
Required for G1/S transition
Phosphorylation;
Interacts with NF-κ B
Transcription activating complex
with AP-1 
 
Key regulator of genes involved
in responses to infection,
inflammation, stress
Part of the replication machinery
of adenovirus
Expression stabilizes and
partially inactivate p53;
expressed in cells that undergo a
mesenchymal
Negatively regulates trans-
activation exerted by c-Myc
Interacts with c-Myc
Vital element of the Wnt
signaling cascade
Interacts with β-catenin
TATA-box-binding complex of
TBP and TAFs
Downstream target of Raf-1;
activator
The sequences between –1068 and –535 were analyzed using Patch
(http://www.gene-regulation.com/pub/programs.html#match) as described in
Materials and Methods. Binding sites for some of the transcription factors
appear more than once.
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CHAPTER IV
DISCUSSION
The goal of this study was to analyze the Dkk-1 promoter region under various
growth conditions and to determine the region of upstream sequences required for its
regulation. We also wanted to identify potential transcription factors involved in Dkk-1
regulation. To do this we first analyzed a construct that contained 1068 base pairs of
upstream Dkk-1 sequence fused to the luciferase reporter gene. The level of luciferase
activity in cells containing this plasmid indicated activity of the Dkk-1 promoter.
NIH3T3 cells containing this construct were grown under different growth conditions,
including expanding and confluent cell populations and serum starvation. Cell cycle
expression was analyzed in NIH3T3 cells by first arresting the cells by serum starvation
and then releasing them back into the cell cycle with complete medium. Finally, the cells
were treated with various growth inhibitors: aphidicolin, MEK 1/2 inhibitor U0126, and
methotrexate. The Dkk-1 promoter activity in the 1068Dkk-1 LUC NIH3T3 cells was
analyzed under each condition. These experiments were repeated with deletion
constructs containing 535 and 228 bp. A summary of the results can be found in Table 2.
In general, we found that Dkk-1 promoter activity is higher in a growing cell population
than in a nondividing population. The 1068 Dkk-1 promoter construct does not appear to
change dramatically during the cell cycle nor is it sensitive to an S phase inhibitor or
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Experimental Treatments
Cell
Line
Confluence Serum
Starvation
Cell Cycle Ras Inhibitor-
U0126
Aphidicolin Methotrexate
1068 Increase up
to Day 3
then
decrease to
Day 5
Decreased by
Day 3; activity
less than control
Gradual
decrease,
increase at
30 hours
Slight decrease at
24 hrs; No effect at
48 hrs
No effect at
24 hrs or 48
hrs
No effect 24 hrs,
decrease at 48
hrs
535 Continual
increase up
to Day 5, no
decrease
Continual
increase, no
decrease; activity
greater than
control
Gradual
decrease
Increase at both 24
hrs and 48 hrs
No effect at
24 hrs,
decrease at 48
hrs
No effect 24 hrs,
increase at 48
hrs
228 Increase up
to Day 3
then
decrease to
Day 5
Continual
increase, no
decrease; activity
greater than
control
Gradual
decrease
Increase at both 24
hrs and 48 hrs
Increase at 24
hrs, decrease
at 48 hrs
No effects at 24
or 48 hrs
pGL3 Increase up
to Day 4
then
decrease at
Day 5
No reduction,
continual
increase, same
level as control
Gradual
decrease
Decrease at 24 hrs,
no effect at 48 hrs
ND Decrease at 24
hrs, no effect at
48 hrs
Table 2. Summary of Results
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U0126. A sequence region between 1068 and 535 appears to be important for
growth regulation of this gene.
Dkk-1 Promoter Activity Decreases in Serum Starved and Density Arrested Cells
Proliferation of normal cells is controlled by the availability of growth factors and
the cell population density. When the cells reach confluency they become quiescent and
arrest in Go. We wanted to see what effect cell density would have on Dkk -1 promoter
activity. The 1068Dkk-1 LUC NIH3T3 cells were plated at a subconfluent density and
allowed to grow in normal medium for five days during which time they reached
confluence. NIH3T3 are immortalized but not transformed cells, hence they stop dividing
when confluent. The promoter activity in the 1068Dkk-1 LUC cells increased more than
two-fold between Days 1 and 2 and continued to increase until Day 3. After Day 3 the
activity began a pattern of decrease and continued to decrease until Day 5. We believe
that the decrease is due to the cells becoming confluent and entering an arrested growth
state. These results are as would be expected. In the study by Gregory et al (2003), they
found that Dkk-1 protein and mRNA levels decreased when mesenchymal stem cells
reach a stationary phase. Because the medium was changed everyday, this decrease
cannot be caused by reduced growth factors in the medium. Overall, these results suggest
that 1068 base pairs is sufficient for down regulation of the Dkk-1 gene promoter in
density-arrested cells.
We also wanted to analyze the promoter activity in the 1068Dkk-1 LUC construct
under serum starved conditions and compare that to its activity when the cells are allowed
to grow in normal medium. We again plated the cells at a subconfluent density and
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allowed them to grow in reduced serum and normal complete medium for three days.
The promoter activity in the cells grown in normal serum increased each of the three
days. The promoter activity increased from Day 1 to Day 2 in the cells grown in low
serum, but then decreased at Day 3. We believe that this decrease is due to the absence
of growth factors in the low serum medium. This lack of sufficient growth factors is
expected to reduce cell signaling, leading to diminished signal being sent to the cells
telling them to divide. These results indicate that the Dkk-1 promoter responds to growth
factor stimulation. Although the cells are subconfluent, the lack of growth factors causes
the cells to enter G0.
Dkk-1 Promoter activity shows little variation during the Cell Cycle
We also wanted to determine how the Dkk-1 promoter responds to re-entry into
the cell cycle after serum starvation. The cells were plated and serum starved and then
released back into the cell cycle by changing to complete medium plus serum. We found
little change in promoter activity from 0 to 24 hours. However, after 24 hours, the
activity increased sharply, more than 2 fold. It is difficult to determine why there was a
decrease in activity in the beginning of the time course. It is likely that the spike in
activity at 30 hours is due to the cells completing a full cell cycle and dividing. Although
the cell number increases at this time, this increase cannot account for the increase in
promoter activity since luciferase activity was standardized to protein content. Thus, the
increase in promoter activity should reflect a real change. It is possible that initial
stimulation of added serum to the cells is not sufficient to activate the Dkk-1 promoter.
Only when the cells are growing more normally does the promoter activity increase.
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The Dkk-1 Promoter Lacks Sensitivity to a Ras Pathway Inhibitor
We wanted to know what would happen to promoter activity in the 1068Dkk-1
LUC NIH3T3 cells when treated with various growth inhibitors. We began with the
MEK 1/2 inhibitor, U0126. This compound is known to inhibit the Ras pathway by acting
as noncompetitive inhibitors to the MEK1 and MEK2 kinases and binding to free MEK
as well as MEK*ERK and MEK*ATP complexes (Reuter et al, 2000). Based on our
finding that the Dkk-1 promoter activity decreases in serum-starved cells, it is expected
that U0126 will also cause a decrease. To test the effects of U0126 on Dkk-1, we plated
the 1068Dkk-1 LUC cells in normal serum and treated them with U0126 at different
concentrations. At higher concentrations, other kinases in addition to MEK 1/2 may be
affected. At 24 hours, we saw that cells treated with 50 µg of U0126 had the lowest
amount of promoter activity. At 48 hours, promoter activity was the highest in cells
treated with 10 µg of U0126. Inhibiting the central Ras pathway via U0126 causes a
reduction in cell signaling. Therefore, we would expect a lower level of Dkk-1 promoter
activity at higher concentrations and longer treatments. We did see that cells treated at
50 µg had the lowest level of activity at 24 hr. But this decrease was not seen at 48 hr.
These results indicate that the Dkk-1 promoter is not very sensitive to inhibition of the
Ras pathway. Thus, the decrease in promoter activity in serum-starved cells is probably
not due to reduction in Ras signaling.
The Dkk-1 Promoter Does Not Respond to an Inhibitor of S Phase
We also treated 1068Dkk-1 LUC cells with aphidicolin. Aphidicolin interrupts
DNA synthesis by inhibiting DNA polymerase α and causes arrest in the G1/S phase. To
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determine how aphidicolin affects Dkk-1, 1068Dkk-1 LUC cells were treated with
different concentrations of aphidicolin for 24 and 48 hours. At 24 hours, we saw that
aphidicolin had little effect on promoter activity. Looking at the data for the cell cycle
expression, we would not expect that aphidicolin would have an effect on activity
because there was little change in promoter activity except towards the very end of the
cell cycle. These results suggest that the Dkk-1 promoter is responding to factors that
determine if the cells enter G1 (from G0) and moves through the cell cycle rather than
events within the cell cycle.
The Dkk-1 Promoter is Sensitive to a Folate Pathway Inhibitor
Finally, we treated the 1068Dkk-1 LUC cells with methotrexate. Methotrexate is
an inhibitor of the folate pathway enzyme, dihydrofolate reductase. Treating cells with
methotrexate will have multiple effects including slowing DNA synthesis in S phase. Our
main interest in methotrexate derives from the finding that Dkk-1 mRNA levels are
reduced in folate depleted cells (Katula et al, submitted). It is expected that methotrexate
would cause a decrease in Dkk-1 promoter activity. We found that methotrexate had no
effect at 24 hours but caused a reduction at all concentrations at 48 hours. One
explanation is that it took additional time to reduce folate levels within the cell
population. Combined with the aphidicolin data (which did not effect Dkk-1 promoter),
these findings suggest that the effect of methotrexate on Dkk-1 promoter activity is not
due to arrest in S phase.
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The Region between -1068 and -535 Appears to be Important for Regulation of Dkk-1
Our next goal was to determine what region of the Dkk-1 upstream sequences was
required for regulation of the Dkk-1 gene. We believe that there is a specific region of
the promoter where transcription factors bind that is necessary for Dkk-1 regulated
activity. To achieve this goal, we obtained deletion constructs of base pair lengths 535
and 228 and analyzed the activity of the promoter under various growth conditions and
during the cell cycle. The same was done for the control vector pGL3. We expected that
one or more of these deletion constructs would display an altered pattern of expression.
For example, under serum starvation, the 535 or 228 would not display a decrease in
promoter activity. This would indicate that the region between 1068 and 535 is required
for correct regulation of Dkk-1 expression. The results of the 535 and 228 construct will
first be compared to the 1068, then the control plasmid, pGL3 will be discussed. The
promoter activity of the three cell lines (1068, 535, and 228) and pGL3-Basic were
initially compared by transient transfection. Our results indicate that the level of
promoter activity is similar for all three constructs (Fig. 4). This indicates that 228 bp
upstream sequences are sufficient for maximum activity in a growing population. The
control plasmid, pGL3, as expected, had very low activity.
The 535Dkk-1LUC NIH3T3 cells showed a distinct pattern of expression when
allowed to grow to confluence for five days. Each day, there was an increase in Dkk-1
promoter activity. Unlike the 1068Dkk-1LUC, which displayed a sharp decrease after
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day three, the 535 had an activity level that did not decrease. When the 535 cells were
allowed to grow under serum starved conditions and in normal medium, there was also an
unexpected pattern. The level of promoter activity increased in both the serum starved
cells and in cells grown in normal serum. In the 1068 cells, promoter activity decreased
under serum starvation. It is not clear why promoter activity is higher in the serum
starved cells. These results suggest that DNA sequences in the 1068 to 535 region are
necessary for suppressing Dkk-1 promoter activity in nongrowing cells. Similar to the
1068 construct, the 535 construct showed little variation in promoter activity during the
cell cycle.
We treated the 535Dkk-1LUC NIH3T3 cells with various inhibitors of the cell
cycle to see how they would affect the activity of Dkk-1 promoter. We saw that MEK ½
U0126 inhibitor had little effect on 1068. In contrast, the 535 cells displayed an increase
in promoter activity when treated with U0126. This suggests that sequences downstream
of 535 are responsive to the Ras pathway. When treated with the S phase inhibitor
aphidicolin, we saw that the 535 cells showed no change in activity for any
concentrations after 24 hours, similar to the 1068. However, at 48 hours promoter
activity decreased at the highest concentration. The promoter activity in 535 cells treated
with methotrexate was not affected at 24 hours, again similar to 1068. However, after 48
hours of treatment, activity increased in contrast to the decrease for 1068. In general, the
inhibitor studies support the notion that sequences between 1068 and 535 contain
sequences involved in regulating Dkk-1 promoter activity.
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The 228Dkk-1LUC NIH3T3 cells were also analyzed under the same conditions
as the 1068 and 535. When the cells were allowed to grow to confluence, we observed a
pattern of activity almost identical to that of the 1068Dkk-1LUC NIH3T3 cells; the
promoter activity increased until Day 3 and then decreased drastically afterwards (Fig. 5).
This can be attributed to the cells reaching a stationary growth phase and ceasing to
divide, causing a decrease in promoter activity. When the cells were grown in normal
medium and serum starved, the results were more similar to 535; there was no decrease in
activity. Unlike 535, the activity level was less than the control. Analysis of the 228Dkk-
1 LUC cells during the cell cycle showed no consequential pattern; activity decreased
over the entire time course. These results are similar to 535. When treated with U0126
inhibitor, the results were similar to 535; activity increased at both 24 and 48 hours.
Contrary to the full length, the highest level of activity was at 50 µM. Cells treated with
aphidicolin were also more similar to 535 than 1068. This pattern is unlike the 1068,
which did not respond to aphidicolin. This is unexpected considering the cell cycle
pattern of expression for 228. However the 228 construct is different and lacks upstream
sequence, and within this region, is responsive to aphidicolin. When treated with
methotrexate, an inhibitor of the enzyme dihydrofolate reductase the 228Dkk-1 LUC
cells showed no change in promoter activity. In general, promoter activity in 228 cells is
distinct but with some similarities to 1068 (confluence) and 535 (serum starvation, cell
cycle, Ras inhibitor, and aphidicolin). This suggests other regulatory sites in the 535 to
228 region.
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Expression from the Control Vector pGL3 Basic Varies
As a control, the vector pGL3 basic was used. It contains the luciferase vector
without any promoter and was used to generate Dkk-1 promoter constructs. We would
expect that under experimental conditions it would show little or no change in activity.
However, in some experiments this was not the case. Under serum starved and growing
and confluent conditions, the overall activity levels were low, as would be expected.
There was little difference between the serum starved cells and cells grown in normal
medium. The promoter activity was low and decreased throughout the cell cycle. When
treated with the inhibitors, there was a strange and unexpected pattern. The pGL3 basic
behaved in some instances like the Dkk-1 luciferase constructs, showing higher levels of
activity at lowest concentrations with the U0126 inhibitor (24 hours) and methotrexate
(24 hours). In other cases it behaved very differently from the Dkk-1 luciferase
constructs. We believe that these behaviors can be attributed to some sequence in the
pGL3 basic vector acting as transcription factor binding sites and transcription initiation
sites (Promega Technical Services).
The Region between 1068 and 535 contains Multiple Binding Sites
Our results suggest that the region between 1068 and 535 contains transcription
factor binding sites required for regulation of the Dkk-1 promoter. Within this region,
two TCF sites have been identified (Gonzales-Sancho et al, 2005) (Fig. 2). It is possible
these sites are required for regulation of the Dkk-1 promoter in serum starved and density
arrested cells. This was not determined by Gonzales-Sancho et al. There also could be
additional transcription factor binding sites within the region. To determine this we
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analyzed the region between 1068 bp and 535 bp upstream using the sequence analysis
tool Patch (http://www.gene-regulation.com/pub/programs.html#match.) Table 1 shows
the results of this analysis. There are numerous potential binding sites based in this
region. Some of these factors are involved in cell growth. However, it is not known if
these factors actually bind to the Dkk-1 sequences. As a start, it will be most critical to
analyze specific mutations of the TCF sites (in the 1068 construct) to determine if these
sites are involved. If they are not involved, then other sites can be examined.
Experimental Concerns
One of the most important issues is that of the control vector used, pGL3.
Because it showed some unusual activity, even though it did not contain any promoter
sequence, it may be necessary to repeat these experiments using the reporter vector pGL4
The pGL4 vector lacks background activity (Promega Technical Services). However,
this would require that all of the Dkk-1 upstream sequences be re-subcloned into this
vector. Another concern is the 535Dkk-1 LUC NIH3T3 cells. The results from this cell
line were unexpected and different from the others. It is possible a group of cells were
selected with altered growth characteristics. We are currently generating entirely new
stable transfected cell lines for all the contructs. Each of these will be assayed under
different growth conditions.
Summary
These studies confirm that Dkk-1 promoter activity is higher in a growing cell
population and decreases as the cells become arrested in G0. These studies further suggest
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that the region of the promoter between 1068 and 535 base pair upstream is required for
regulated expression of the Dkk-1 gene under different growth conditions. We analyzed
the activity under different conditions and the cell cycle and treated the cells with various
inhibitors. We found that Dkk-1 promoter activity decreases in serum starved and
density arrested cells and shows little variation during the cell cycle. When the Dkk-1
LUC NIH3T3 cells were treated with inhibitors, we found that the promoter is not
sensitive to a Ras pathway inhibitor, MEK U0126, it does not respond to aphidicolin, an
inhibitor of S phase and the promoter is sensitive to methotrexate, a folate pathway
inhibitor. After analyzing the region we believe required for regulation we found that
there are specific binding sites required for regulation and mutating those sites could alter
Dkk-1 gene expression under different growth conditions. Since the Dkk-1 promoter was
found not to be sensitive to a Ras pathway inhibitor, it is unlikely that reduced Ras
signaling is responsible for the decrease in Dkk-1 promoter activity in serum starved
cells. The Dkk-1 promoter does not appear to vary significantly during the cell cycle and
is not affected by an inhibitor of S phase. Together these results suggest that the Dkk-1
promoter is regulated relative to the growth state of the cell population and not the cell
cycle. However, the Dkk-1 promoter is sensitive to methotrexate. These studies further
suggest that sequences between 1068 and 535 in the Dkk-1 promoter are important for
regulation. Computer analysis reveals numerous potential transcription factor binding
sites. Further studies will focus on this sequence region.
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